

Supplementary Material:

| First author and year of publication | Reason for exclusion |
|--------------------------------------|--|
| Acocella A et al. 2010 | Onlay block graft |
| Alérico FA et al. 2019 | Unclear measurement methodology |
| Amorfini L et al. 2014 | Simultaneous implant placement |
| Cordaro L et al. 2011 | Onlay block graft |
| D'Amato S et al. 2015 | Insufficient sample size |
| De Stavola L et al. 2013 | Vertical bone augmentation |
| Ersanli S et al. 2004 | Use of other biomaterials |
| Ersanli S et al. 2016 | Use of other biomaterials |
| Gulinelli JL et al. 2017 | Onlay block graft |
| Holtzclaw DJ et al. 2010 | Split-ridge technique |
| Jung RE et al. 2009 | Simultaneous implant placement |
| Khoury F et al. 2019 | Vertical bone augmentation |
| Korsch M et al. 2019 | Use of other biomaterials |
| Korzh DG et al. 2019 | Full-Text not accessible |
| Moukrioti J et al. 2019 | Unclear measurement methodology |
| Meloni SM et al. 2017 | Sample studied reported in another study |
| Novy LFS et al. 2019 | Vertical bone augmentation |
| Peñarrocha-Diago M et al. 2013 | Use of other biomaterials |
| Restoy-Lozano A et al. 2015 | Vertical bone augmentation |
| Santana RB et al. 2015 | Onlay block graft |
| Schlee M et al. 2014 | Use of other biomaterials |
| Schwartz-Arad D et al. 2005 | Onlay block graft |
| Spin-Neto R et al. 2014 | Onlay block graft |
| Spin-Neto R et al. 2013 | Onlay block graft |
| Spin-Neto R et al. 2015 | Onlay block graft |
| Spin-Neto R et al. 2013 | Onlay block graft |
| Thoma DS et al. 2018 | Use of other biomaterials |
| Thoma DS et al. 2019 | Use of other biomaterials |

| | |
|-----------------------|---------------------------|
| Urban IA et al. 2011 | Use of other biomaterials |
| Urban IA et al. 2017 | Use of other biomaterials |
| Verdugo F et al. 2011 | Onlay block graft |
| Verdugo F et al. 2012 | Onlay block graft |

Table S1 . List of excluded articles and reason for exclusion.

| Authors | Year | Study design | Random generation of the secuence | Allocation concealment | Blinding of participants and staff | Blinding of evaluator | Incomplete data | Selective notification of results | Another bias |
|------------------|------|----------------|-----------------------------------|------------------------|------------------------------------|-----------------------|-----------------|-----------------------------------|----------------|
| Bartols A et al. | 2018 | Clinical trial | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Atef et al | 2019 | Clinical trial | Low risk | Not clear risk | Not clear risk | Not clear risk | Low risk | Low risk | Not clear risk |
| Atef M et al. | 2020 | Clinical trial | Low risk | Not clear risk | Not clear risk | Not clear risk | Low risk | Low risk | Not clear risk |

Table S2. Cochrane Risk of bias of clinical trials.

| Authors | Year | Study design | Clear inclusión criteria | Standard and reliable condition measure | Correct condition identification | Consecutive inclusión of participants | Complete inclusión of participants | Complete demographic information | Clinical information | Clear follow up outcomes | Clear reporting of the demographic information of sites/clinic | Statistical analysis appropiate |
|--------------------|------|--------------|--------------------------|---|----------------------------------|---------------------------------------|------------------------------------|----------------------------------|----------------------|--------------------------|--|---------------------------------|
| Saravanan P et al. | 2013 | Case series | Yes | Yes | Yes | Not clear | Yes | Not clear | Yes | Not clear | Not clear | Yes |
| Urban IA et al. | 2013 | Case series | Yes | Yes | Yes | Not clear | Yes | Yes | Yes | Yes | Yes | Yes |
| Meloni SM et al. | 2019 | Case Series | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |

Table S3. Joanna Briggs Risk of bias of case series.